Sellas' Phase 3 AML Trial Reaches 80th Death, Triggering Final Analysis

PUBT · 4d ago
Sellas' Phase 3 AML Trial Reaches 80th Death, Triggering Final Analysis
  • Sellas Life Sciences' Phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia reached its prespecified 80th death, triggering final analysis.
  • Preliminary topline results for the trial's primary endpoint of overall survival are expected this quarter.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sellas Life Sciences Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610280835PRIMZONEFULLFEED9854999) on October 28, 2026, and is solely responsible for the information contained therein.